Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing Chronic Pseudomonas aeruginosa Infections.
- 1Clinical Infection, Microbiology and Immunology (CIMI), University of Liverpool, Liverpool, UK.
Abstract
Pseudomonas aeruginosa is the leading cause of chronic respiratory infection in people with cystic fibrosis (pwCF) and remains a major driver of morbidity and premature mortality. The unique environment of the CF lung promotes persistent colonisation, biofilm formation, and the emergence of multidrug-resistant (MDR) phenotypes, severely limiting the effectiveness of conventional antibiotic therapies. Despite aggressive and prolonged antibiotic regimens, eradication of chronic P. aeruginosa infection is rarely achieved, and repeated exposure accelerates resistance development. Consequently, there is an urgent need for alternative or adjunctive therapeutic strategies. Bacteriophage (phage) therapy has re-emerged as a promising approach for treating MDR P. aeruginosa infections due to its strain specificity, self-amplifying activity, and capacity to disrupt biofilms. Importantly, phage-driven selection pressure can impose fitness costs on bacteria, including reduced virulence and increased susceptibility to antibiotics, providing a potential route to antimicrobial resensitisation. However, translating phage therapy into routine clinical practice faces challenges, particularly in the context of CF lung disease, where heterogeneous bacterial populations, thick mucus, biofilms, and host immune responses complicate treatment efficacy. This scoping review synthesises current understanding of P. aeruginosa pathogenesis in CF, focusing on antibiotic resistance mechanisms, virulence factors that function as phage receptors, and the evolutionary trade-offs exploited by phage therapy, including the role of phage-encoded depolymerases that degrade protective biofilms and bacterial defence mechanisms that drive phage resistance. We critically evaluate clinical evidence supporting phage use in pwCF, highlighting key limitations in existing studies, and priorities for future research required to establish phage therapy as a viable, regulated treatment option.
Related
- Bacteriophage susceptibility varies within chronic Pseudomonas aeruginosa lung infections
- Phage therapy against Pseudomonas aeruginosa biofilm infections: challenges and advanced strategies
- Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy
- Bacteriophage PAK_P3 genome structuration and dynamics during infection of Pseudomonas aeruginosa reveal specific interaction patterns
- The bacteriophage transcription factor Gp53 suppresses cell division and regulates Pseudomonas aeruginosa physiology
BibTeX
@article{puthenpurayil2026bacteriophage,
title = {{Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing Chronic Pseudomonas aeruginosa Infections.}},
author = {Ayona Puthenpurayil and Lauren Gordon and Joanne L Fothergill},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s612130},
url = {https://europepmc.org/article/MED/42898652},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing Chronic Pseudomonas aeruginosa Infections.
AU - Ayona Puthenpurayil
AU - Lauren Gordon
AU - Joanne L Fothergill
PY - 2026
DA - 2026/10/14
JO - Drug design, development and therapy
DO - 10.2147/dddt.s612130
UR - https://europepmc.org/article/MED/42898652
AB - Pseudomonas aeruginosa is the leading cause of chronic respiratory infection in people with cystic fibrosis (pwCF) and remains a major driver of morbidity and premature mortality. The unique environment of the CF lung promotes persistent colonisation, biofilm formation, and the emergence of multidrug-resistant (MDR) phenotypes, severely limiting the effectiveness of conventional antibiotic therapies. Despite aggressive and prolonged antibiotic regimens, eradication of chronic P. aeruginosa infection is rarely achieved, and repeated exposure accelerates resistance development. Consequently, there is an urgent need for alternative or adjunctive therapeutic strategies. Bacteriophage (phage) therapy has re-emerged as a promising approach for treating MDR P. aeruginosa infections due to its strain specificity, self-amplifying activity, and capacity to disrupt biofilms. Importantly, phage-driven selection pressure can impose fitness costs on bacteria, including reduced virulence and increased susceptibility to antibiotics, providing a potential route to antimicrobial resensitisation. However, translating phage therapy into routine clinical practice faces challenges, particularly in the context of CF lung disease, where heterogeneous bacterial populations, thick mucus, biofilms, and host immune responses complicate treatment efficacy. This scoping review synthesises current understanding of P. aeruginosa pathogenesis in CF, focusing on antibiotic resistance mechanisms, virulence factors that function as phage receptors, and the evolutionary trade-offs exploited by phage therapy, including the role of phage-encoded depolymerases that degrade protective biofilms and bacterial defence mechanisms that drive phage resistance. We critically evaluate clinical evidence supporting phage use in pwCF, highlighting key limitations in existing studies, and priorities for future research required to establish phage therapy as a viable, regulated treatment option.
SN - 1177-8881
ER -